STEPHEN DAVID NIMER

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells
    Stephen D Nimer
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 23:4249-54. 2004
  2. ncbi request reprint Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q
    Stephen D Nimer
    Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    J Clin Oncol 24:2576-82. 2006
  3. pmc DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions
    Monica Morales
    Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Cornell University Graduate School of Medical Sciences, New York, NY 10021, USA
    Cancer Res 68:2186-93. 2008
  4. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
  5. pmc AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion
    James C Mulloy
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 102:4016-21. 2005
  6. pmc Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation
    Joseph M Scandura
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:15231-6. 2004
  7. ncbi request reprint Myelodysplastic syndromes clinical practice guidelines in oncology
    Peter L Greenberg
    Stanford Hospital and Clinics, Stanford, CA, USA
    J Natl Compr Canc Netw 4:58-77. 2006
  8. ncbi request reprint Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells
    Donal MacGrogan
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, New York 10021, USA
    Genes Chromosomes Cancer 41:203-13. 2004
  9. ncbi request reprint TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression
    Keiko Asakura
    Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mol Cancer Res 2:339-47. 2004
  10. ncbi request reprint Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins
    Anja Moldenhauer
    Institute for Transfusion Medicine and Immunehaematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Leukoc Biol 76:623-33. 2004

Research Grants

  1. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    Stephen Nimer; Fiscal Year: 2005
  2. The function of I(3)mbt in hematopoietic cancers
    Stephen Nimer; Fiscal Year: 2007
  3. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    Stephen Nimer; Fiscal Year: 2007
  4. Vitamin D3 inducible Genes Mediating Differentiation
    Stephen Nimer; Fiscal Year: 2004
  5. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    STEPHEN DAVID NIMER; Fiscal Year: 2010

Collaborators

Detail Information

Publications55

  1. ncbi request reprint Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells
    Stephen D Nimer
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 23:4249-54. 2004
    ..The direct effects of AML1-ETO on human and murine HSCs, and the potentially cooperating events that may contribute to its leukemogenic properties, are discussed...
  2. ncbi request reprint Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q
    Stephen D Nimer
    Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    J Clin Oncol 24:2576-82. 2006
    ..This review highlights some issues about the classification and treatment of del(5q) MDS...
  3. pmc DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions
    Monica Morales
    Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Cornell University Graduate School of Medical Sciences, New York, NY 10021, USA
    Cancer Res 68:2186-93. 2008
    ....
  4. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  5. pmc AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion
    James C Mulloy
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 102:4016-21. 2005
    ....
  6. pmc Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation
    Joseph M Scandura
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:15231-6. 2004
    ..Our studies identify a molecular pathway by which TGFbeta mediates its cytostatic effects on human hematopoietic cells and suggests an explanation for the frequent silencing of p57 expression...
  7. ncbi request reprint Myelodysplastic syndromes clinical practice guidelines in oncology
    Peter L Greenberg
    Stanford Hospital and Clinics, Stanford, CA, USA
    J Natl Compr Canc Netw 4:58-77. 2006
  8. ncbi request reprint Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells
    Donal MacGrogan
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, New York 10021, USA
    Genes Chromosomes Cancer 41:203-13. 2004
    ..These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia...
  9. ncbi request reprint TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression
    Keiko Asakura
    Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mol Cancer Res 2:339-47. 2004
    ....
  10. ncbi request reprint Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins
    Anja Moldenhauer
    Institute for Transfusion Medicine and Immunehaematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Leukoc Biol 76:623-33. 2004
    ..This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins...
  11. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006
    ..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia...
  12. ncbi request reprint The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells
    H Daniel Lacorazza
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Cancer Cell 9:175-87. 2006
    ..Thus, MEF plays an important role in the decision of stem/primitive progenitor cells to divide or remain quiescent by regulating their entry to the cell cycle...
  13. ncbi request reprint Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    ..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
  14. pmc Is it important to decipher the heterogeneity of "normal karyotype AML"?
    Stephen D Nimer
    Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, NY 1275 York Avenue, New York, NY 10021, USA
    Best Pract Res Clin Haematol 21:43-52. 2008
    ..Increased understanding of the biological consequences of at least some of these mutations in "normal karyotype AML" is leading to more targeted approaches to develop more effective treatments for this disease...
  15. doi request reprint Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  16. pmc Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity
    Xinyang Zhao
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Dev 22:640-53. 2008
    ..These arginine methylation sites and the dynamic regulation of corepressor binding are lost in the leukemia-associated RUNX1-ETO fusion protein, which likely contributes to its dominant inhibitory activity...
  17. pmc CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
    Ping Zhou
    Sloan Kettering Institute, Department of Medicine, New York, NY 10021, USA
    Blood 111:3403-6. 2008
    ..These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis...
  18. pmc HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR
    Richard F Schlenk
    University of Ulm, Ulm, Germany
    Biol Blood Marrow Transplant 14:187-96. 2008
    ..These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT...
  19. pmc Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7
    Benjamin J Thompson
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Exp Med 205:1395-408. 2008
    ....
  20. pmc The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2
    Yan Liu
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 575, New York, NY 10021, USA
    Mol Cell Biol 26:3114-23. 2006
    ..The tight regulation of MEF levels during the cell cycle contributes to its effects on regulating cell cycle entry and cell proliferation...
  21. pmc Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    David H Chang
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Blood 108:618-21. 2006
    ..Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors...
  22. ncbi request reprint Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
    Craig H Moskowitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
    Br J Haematol 124:645-52. 2004
    ..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy...
  23. ncbi request reprint Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission
    Julie M Vose
    University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 10:116-27. 2004
    ..Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death...
  24. ncbi request reprint Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination
    Ping Zhou
    Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 102:477-9. 2003
    ..1%) or 0.5 x 10(4) clonotypic cells per kilogram (range, 0-41.2 x 10(4)/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P <.01). Melphalan-mobilized SCCs contain minimal clonotypic contamination...
  25. ncbi request reprint De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19
    Juan C Cigudosa
    Cytogenetics Unit, Department of Human Genetics, Spanish National Cancer Center, Melchior Fernandez Almagro, 3 28029 Madrid, Spain
    Genes Chromosomes Cancer 36:406-12. 2003
    ..1, 20q11.2, and 21q11.2. This is the first molecular cytogenetic description of the karyotype abnormalities present in patients with ERL. It should assist in the identification of genes involved in erythroleukemogenesis...
  26. ncbi request reprint The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6)
    Piernicola Boccuni
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute for Cancer Research, New York, New York 10021, USA
    J Biol Chem 278:15412-20. 2003
    ..We speculate that the interaction of TEL with H-L(3)MBT can direct a PcG complex to genes repressed by TEL, stabilizing their repressed state...
  27. ncbi request reprint Isolation and characterization of runxa and runxb, zebrafish members of the runt family of transcriptional regulators
    Caroline Erter Burns
    Children s Hospital Boston, Boston, MA, USA
    Exp Hematol 30:1381-9. 2002
    ..The aim of this study was to isolate runt-related genes in a genetically and embryologically exploitable system, the zebrafish, and characterize their function during hematopoietic development...
  28. doi request reprint Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:826-32. 2008
    ....
  29. ncbi request reprint Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells
    Jorg Cammenga
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    Blood 101:2206-14. 2003
    ..Given the known differences in murine and human promoter regulatory sequences, this inducible system allows the identification of transcription factor target genes in a physiologic, human hematopoietic progenitor cell background...
  30. ncbi request reprint The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells
    H Daniel Lacorazza
    Laboratory of Molecular Aspects of Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunity 17:437-49. 2002
    ..Our results uncover a specific role of MEF in the development and function of NK cells and in innate immunity...
  31. ncbi request reprint Transcription factor fusions in acute leukemia: variations on a theme
    Joseph M Scandura
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Oncogene 21:3422-44. 2002
    ..g., co-repressor molecules or co-activator molecules). It is these shared features that constitute the 'variations on the theme' that underling the aberrant growth and differentiation that is the hallmark of acute leukemia cells...
  32. ncbi request reprint The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells
    James C Mulloy
    Laboratory of Molecular Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
    Blood 99:15-23. 2002
    ..Thus, AML1-ETO enhances the self-renewal of pluripotent stem cells, the physiological target of many acute myeloid leukemias...
  33. ncbi request reprint Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Paul A Hamlin
    Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
    Blood 102:1989-96. 2003
    ..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
  34. ncbi request reprint High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Neurooncol 65:127-34. 2003
    ....
  35. ncbi request reprint Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells
    Cyrus V Hedvat
    Laboratory of Molecular Aspects of Hematopoiesis, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Biol Chem 279:6395-400. 2004
    ..MEF overexpression is sufficient to induce IL-8 protein expression, and reduction in MEF expression (using RNA interference) results in decreased IL-8 levels. These data demonstrates that MEF is an important regulator of IL-8 expression...
  36. ncbi request reprint Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes
    Shin ichiro Fujii
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Br J Haematol 122:617-22. 2003
    ..This severe and selective deficiency of an important immune regulatory cell may contribute to the pathogenesis of MDS...
  37. ncbi request reprint Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Tarun Kewalramani
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 103:3684-8. 2004
    ..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
  38. ncbi request reprint Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
    Cyrus V Hedvat
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
    Br J Haematol 122:728-44. 2003
    ..Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion...
  39. ncbi request reprint Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element
    James C Mulloy
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Mail Location 7013, Cincinnati, OH 45229, USA
    Blood 102:4369-76. 2003
    ....
  40. ncbi request reprint The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesis
    H Daniel Lacorazza
    Laboratory of Molecular Aspects of Hematopoiesis, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood Cells Mol Dis 31:342-50. 2003
    ..MEF interacts with other TFs such as AML1 (Runx1) and with the cyclin A/cdk2 kinase complex. In this review, we discuss the biology of MEF in the context of the other members of this family of transcriptional regulators...
  41. ncbi request reprint Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
    Lauren E Abrey
    Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4151-6. 2003
    ..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
  42. ncbi request reprint Cytogenetic characterization reveals that the SAM-1 erythroid cell line is derived from K-562 cells
    Sara Alvarez
    Blood 100:3435-6. 2002
  43. ncbi request reprint Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma
    Cyrus V Hedvat
    Laboratory of Cancer Genetics, Cell Biology Program, Department of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:968-74. 2002
    ..This extensive expression profile of B-cell NHLs and HL tissues discloses the ability of TMAs to rapidly screen a large series of cases and represents the first report of method validation for this technique in the study of lymphoma...
  44. ncbi request reprint Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
    Thomas Kindler
    Johannes Gutenberg University Mainz, 3rd Med Department, Mainz, Germany
    Blood 105:335-40. 2005
    ..Since FLT3 tyrosine kinase inhibitors (TKIs) such as PKC412 are currently being investigated in clinical trials in AML, extended sequence analysis of FLT3 may be helpful in defining the spectrum of TKI-sensitive FLT3 mutations in AML...
  45. doi request reprint Myelodysplastic syndromes
    Stephen D Nimer
    Division of Hematologic Oncology and Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 111:4841-51. 2008
    ....
  46. ncbi request reprint Chromosome 19 abnormalities are commonly seen in AML, M7
    Stephen D Nimer
    Blood 100:3838; author reply 3838-9. 2002
  47. ncbi request reprint PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis
    Gang Huang
    Hematology Oncology Division, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Genet 40:51-60. 2008
    ..1 expression rescued or partially rescued each phenotype. Thus, our data demonstrate that PU.1 is a major downstream target gene of AML1...
  48. ncbi request reprint L3MBTL1, a histone-methylation-dependent chromatin lock
    Patrick Trojer
    Howard Hughes Medical Institute, University of Medicine and Dentistry of New Jersey, 683 Hoes Lane, Piscataway, NJ 08854, USA
    Cell 129:915-28. 2007
    ..Consistently, L3MBTL1 was found to negatively regulate the expression of a subset of genes regulated by E2F, a factor that interacts with Rb...
  49. pmc Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells
    Vladimir Jankovic
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:1260-5. 2007
    ..Thus, Id1 appears to regulate the fate of HSCs by acting as a true inhibitor of differentiation...
  50. ncbi request reprint Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma
    Tarun Kewalramani
    Hematology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:202-7. 2006
    ..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
  51. ncbi request reprint Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    Richard M Stone
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 105:54-60. 2005
    ..PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy...
  52. ncbi request reprint Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    ..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
  53. pmc OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1
    Ying Wei Lin
    Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889 5105, USA
    Cancer Res 65:7151-8. 2005
    ..In addition, growth of leukemic cell lines established from OLIG2/LMO1 transgenic mice was suppressed by a gamma-secretase inhibitor, suggesting that Notch1 up-regulation is important for the proliferation of OLIG2-LMO1 leukemic cells...
  54. ncbi request reprint Malignant brain tumor repeats: a three-leaved propeller architecture with ligand/peptide binding pockets
    Wooi Koon Wang
    Cellular Biochemistry and Biophysics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Structure 11:775-89. 2003
    ..Strikingly, phenotypic alterations resulting from point mutations or deletions in the mbt repeats of the related Drosophila SCM protein are clustered in and around the ligand binding pocket...
  55. pmc Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
    Daniel J DeAngelo
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3674-81. 2006
    ..Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity...

Research Grants20

  1. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    Stephen Nimer; Fiscal Year: 2005
    ..These studies will contribute greatly to advances in the fields of stem cell transplantation and immune regulation. ..
  2. The function of I(3)mbt in hematopoietic cancers
    Stephen Nimer; Fiscal Year: 2007
    ..The PcG family of proteins is being increasingly implicated in carcinogenesis, and these studies will provide insights into the role that l(3)mbt plays in hematologic malignancies. ..
  3. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    Stephen Nimer; Fiscal Year: 2007
    ..abstract_text> ..
  4. Vitamin D3 inducible Genes Mediating Differentiation
    Stephen Nimer; Fiscal Year: 2004
    ..The functional requirement of the DRIP coactivator complex in mediating VDR and RAR transactivation, in the context of nuclear receptor-dependent myeloid differentiation, will be determined. ..
  5. FUNCTION OF MEF IN HEMATOPOIETIC CELLS
    STEPHEN DAVID NIMER; Fiscal Year: 2010
    ..We hope that the information gained can be exploited to improve the therapeutic index of current cancer treatments and devise new therapeutic approaches. ..